Abstract | OBJECTIVE: METHODS: CHB patients were treated with PEG-IFNalpha-2a for a minimum of 48 weeks. All patients were followed up for 26 weeks post-treatment. Patients with HBV DNA > or = 1 x 10(8) copies/ml were combined with NUC ( adefovir or entecavir) treatment. Patients with ALT > 500 U/L at baseline or ALT > 300 U/L after first injection of PEG-IFNalpha-2a received bicyclol treatment for 1-2 months (treatment group). Patients with 2 x ULN < ALT < 300 U/L and ALT < 300 U/L during treatment were enrolled into PEG-IFNalpha-2a +/- NUC antiviral monotherapy (control group). Responses defined as HBV DNA < 1 x 10(3) copies/ml, normal serum ALT, and HBeAg/ HBsAg loss and seroconversion were analyzed at 26 weeks post-treatment. RESULTS: A total of 54 patients (44 HBeAg positive, 10 HBeAg negative) were divided into two groups according to combination of bicyclol: treatment group (n = 20)--those who received combinition therapy with PEG-IFNalpha-2a +/- NUC and bicyclol, and control group (n = 34)--those who were treated with PEG-IFNalpha-2a +/- NUC antiviral monotherapy. During the first month of treatment, ALT levels declined gradually in treatment group. At 26 weeks post-treatment, the rates of ALT normalization and HBV DNA below the limit of 1 x 10(3) copies/ml were similar in both groups. Six patients in treatment group achieved HBsAg seroconversion at 26 weeks post-treatment, whereas so did 4 patients of control group (30% vs. 11.8%, P = 0.044). CONCLUSION:
Bicyclol could significantly relief elevation of ALT induced by the IFN treatment.
|
Authors | Qin Ni, Xie Tian-Sheng, Li Min-Wei, Liu Ke-Zhou |
Journal | Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology
(Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi)
Vol. 26
Issue 2
Pg. 114-6
(Apr 2012)
ISSN: 1003-9279 [Print] China |
PMID | 23002549
(Publication Type: Journal Article)
|
Chemical References |
- Biphenyl Compounds
- DNA, Viral
- Hepatitis B Surface Antigens
- Hepatitis B e Antigens
- Interferon-alpha
- Recombinant Proteins
- Polyethylene Glycols
- bicyclol
- Alanine Transaminase
- peginterferon alfa-2a
|
Topics |
- Alanine Transaminase
(blood)
- Biphenyl Compounds
(administration & dosage, adverse effects)
- DNA, Viral
(analysis)
- Drug Therapy, Combination
- Hepatitis B Surface Antigens
(blood)
- Hepatitis B e Antigens
(blood)
- Hepatitis B, Chronic
(blood, drug therapy)
- Humans
- Interferon-alpha
(administration & dosage, adverse effects)
- Polyethylene Glycols
(administration & dosage, adverse effects)
- Recombinant Proteins
(administration & dosage, adverse effects)
|